Harmony Biosciences (HRMY) Tops Q4 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Harmony Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
February 28, 2022 7:30 AM ESTWAKIX® (pitolisant) Net Revenue Increased 62% Year-over-Year to $91.2 Million for Fourth Quarter 2021 and 91% to $305.4 Million for Full Year
Achieved First Full Year of Profitability and Net income was $22.7 Million for the Fourth Quarter 2021
Average Number of Patients on WAKIX Increased to ~3,800
On Track to Initiate the Phase 3 Clinical Trial in Patients with Idiopathic Hypersomnia First Half of This Year
 Year-End 2021 Cash and Cash Equivalents of Approximately $234 Million
Conference Call and Webcast to be Held Today at 8:30 a.m. ETÂ
... More